Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Mount Sinai Hospital · Universitat de Barcelona · +28 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
412
total citations
- FWCI
- 77.10
- Percentile
- 100%
- References
- 30
Citations per year
Authors
209- JMJosep M. LlovetCorresponding
Mount Sinai Hospital, Universitat de Barcelona, Icahn School of Medicine at Mount Sinai
- MKMasatoshi Kudo
Kindai University
- PMPhilippe Merle
Hôpital de la Croix-Rousse, Hospices Civils de Lyon
- TMTim Meyer
Royal Free London NHS Foundation Trust, London Cancer, University College London
- SQShukui Qin
Topics & keywords
Topics
Keywords
- Lenvatinib
- Medicine
- Pembrolizumab
- Hepatocellular carcinoma
- Internal medicine
- Placebo
- Oncology
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.